CD38 and neuroendocrine carcinoma: While the mechanism of such shifts is unknown, the correlation pattern seen in the clinical samples may find an explanation in the light of the recent clinical data [20] where CD38 was significantly elevated in benign prostate tissue but displayed a progressively reduced expression between the localized, metastatic, and neuroendocrine cancer subtypes, suggesting a tumor-suppressing role.